A Phase 2B/3 Open-label Study of EPI-743 in Children with Leigh Syndrome

Trial Profile

A Phase 2B/3 Open-label Study of EPI-743 in Children with Leigh Syndrome

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Vatiquinone (Primary)
  • Indications Leigh disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 28 Oct 2015 Status changed from recruiting to completed according to a Sumitomo Dainippon Pharma media release.
    • 11 Mar 2014 The first patient has been enrolled, according to an Edison Pharmaceuticals media release.
    • 11 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top